An interferon-free combination of the protease inhibitor ABT-450 with ritonavir ( ABT-450 / r ) , the nonnucleoside polymerase inhibitor ABT-333 , and ribavirin showed efficacy against the hepatitis C virus ( HCV ) in a pilot study involving patients with HCV genotype 1 infection .